Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Regulation FD Disclosure

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Regulation FD Disclosure
Item 7.01.

Regulation FD Disclosure.
Story continues below

Titan Pharmaceuticals, Inc. has updated its corporate presentation which will be posted on its website and used for future presentations. A copy is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The foregoing information, including the presentation attached hereto as an exhibit, is being furnished to Item 7.01 of this Current Report and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement to the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits
Exhibit No. Description
99.1 Corporate Presentation

EX-99.1 2 tv512902_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   Copyright © Titan Pharmaceuticals 2019 Not for Promotional Use Titan Pharmaceuticals Titan Corporate Presentation | February 2019     This presentation contains forward – looking statements within the meaning of Section 27 A of the Securities Act of 1933 ,…
To view the full exhibit click here

About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

An ad to help with our costs